These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34363297)

  • 21. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
    Scharre DW; Vekeman F; Lefebvre P; Mody-Patel N; Kahler KH; Duh MS
    Drugs Aging; 2010 Nov; 27(11):903-13. PubMed ID: 20964464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacotherapy for Alzheimer's disease].
    Verhey FR
    Tijdschr Psychiatr; 2006; 48(1):17-26. PubMed ID: 16955982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Medical treatment of Alzheimer's disease].
    Johannsen P
    Ugeskr Laeger; 2006 Oct; 168(40):3424-9. PubMed ID: 17032609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.
    Repantis D; Laisney O; Heuser I
    Pharmacol Res; 2010 Jun; 61(6):473-81. PubMed ID: 20193764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
    Sonde L; Johnell K
    PLoS One; 2013; 8(2):e57161. PubMed ID: 23437334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication adherence in patients with dementia: an Austrian cohort study.
    Haider B; Schmidt R; Schweiger C; Forstner T; Labek A; Lampl C
    Alzheimer Dis Assoc Disord; 2014; 28(2):128-33. PubMed ID: 24113561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
    Taipale H; Tanskanen A; Koponen M; Tolppanen AM; Tiihonen J; Hartikainen S
    Int Clin Psychopharmacol; 2014 Jul; 29(4):216-23. PubMed ID: 24608822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.
    Ann Intern Med; 2008 Mar; 148(5):I41. PubMed ID: 18316749
    [No Abstract]   [Full Text] [Related]  

  • 31. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New drugs for Alzheimer's disease in Japan.
    Takeda M; Tanaka T; Okochi M
    Psychiatry Clin Neurosci; 2011 Aug; 65(5):399-404. PubMed ID: 21851448
    [No Abstract]   [Full Text] [Related]  

  • 34. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
    Truter I
    Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
    Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.
    Lee JH
    Naunyn Schmiedebergs Arch Pharmacol; 2022 May; 395(5):535-546. PubMed ID: 35122115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.